Immune Design Corp (NASDAQ:IMDZ) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of equities analysts recently issued reports on IMDZ shares. Cowen restated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. Wells Fargo & Co cut Immune Design from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Finally, Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a report on Friday, November 10th.

In other Immune Design news, Director Peter Svennilson purchased 2,681,000 shares of the stock in a transaction dated Friday, October 27th. The shares were acquired at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Leo Guthart purchased 20,000 shares of the stock in a transaction dated Monday, January 8th. The shares were acquired at an average price of $3.90 per share, for a total transaction of $78,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 5,310,000 shares of company stock worth $21,855,900 and sold 13,959 shares worth $58,209. Insiders own 20.70% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. purchased a new position in shares of Immune Design during the second quarter valued at $118,000. Virtu KCG Holdings LLC purchased a new position in shares of Immune Design during the second quarter valued at $153,000. Dimensional Fund Advisors LP grew its holdings in shares of Immune Design by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Immune Design by 53.9% during the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 6,896 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Immune Design by 95.1% during the second quarter. New York State Common Retirement Fund now owns 20,100 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 9,799 shares in the last quarter. Institutional investors and hedge funds own 29.34% of the company’s stock.

Immune Design (NASDAQ:IMDZ) opened at $3.60 on Wednesday. The stock has a market capitalization of $173.01, a price-to-earnings ratio of -1.69 and a beta of 2.36. Immune Design has a 1-year low of $3.50 and a 1-year high of $13.05.

Immune Design (NASDAQ:IMDZ) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. research analysts forecast that Immune Design will post -1.89 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2018/01/17/immune-design-corp-imdz-receives-consensus-rating-of-hold-from-analysts.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.